PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PacBio (NASDAQ: PACB) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT (1:30 PM ET) in San Francisco.
A live webcast will be available on the company investor site and a replay will be posted for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
In the Dec 31 session, PACB gained 8.09%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Investor conference | Neutral | -2.9% | Announcement of participation in Piper Sandler healthcare conference with webcast access. |
| Nov 13 | Investor conferences | Neutral | -1.2% | Plan to attend multiple investor conferences with fireside chats and webcasts. |
| Nov 05 | Earnings update | Neutral | -4.3% | Q3 2025 results with lower revenue but improved margins and narrowed losses. |
| Nov 05 | Clinical data | Positive | -4.3% | Study showing HiFi sequencing detected all known pathogenic variants in complex regions. |
| Nov 04 | Regulatory approval | Positive | -10.7% | First clinical-grade long-read sequencer approval in China via Berry Genomics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and regulatory milestones were followed by negative price reactions, while routine conference announcements also coincided with modest declines.
Over the last two months, PacBio reported Q3 2025 results, highlighted major clinical research demonstrating its HiFi genomes, and supported a partner’s first regulatory approval for clinical long-read sequencing in China. Despite these developments, 24-hour price reactions were negative across earnings, clinical, and regulatory news. The company also announced multiple investor and healthcare conference appearances, which saw smaller share price declines. Today’s J.P. Morgan conference presentation continues this pattern of investor-focused outreach following a series of operational and scientific milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT (1:30 PM ET) in San Francisco, California.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
